Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.

Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

US pharma giant Pfizer has ended all development and commercialization activities relating to fidanacogene elaparvovec, a ...

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

In another sign of the challenges facing gene therapy developers, Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has ...

The move comes weeks after Pfizer terminated its partnership with Sangamo Therapeutics for another hemophilia gene therapy.

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

NEW YORK/TOKYO -- Pfizer will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the drugmaker dropped its other similar treatment ...